Healthy Skepticism Library item: 3604

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Roizen R.
Why I oppose drug company payment of physician/investigators on a per patient/subject basis
IRB: a review of human subjects research 1988; 10:(1):9-10

Abstract:

The author reviews arguments about whether patients/subjects should be informed about per capita payments to patients and whether such payments are ethical.

Keywords:
*analysis/United States/Institutional Research Board/IRB/drug company sponsored research/doctors/patients/regulation of promotion/conflict of interest/reimbursement to doctors/ATTITUDES REGARDING PROMOTION: HEALTH PROFESSION STUDENTS/ATTITUDES REGARDING PROMOTION: HEALTH PROFESSIONALS/ETHICAL ISSUES IN PROMOTION: GIFT GIVING/ETHICAL ISSUES IN PROMOTION: PAYMENTS IN STUDIES/REGULATION, CODES, GUIDELINES: COMPLIANCE, SANCTIONS, STANDARDS

Please
Click to Register

(read more)

then
Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts

If there is something you don't like, please tell us. If you like our work, please tell others.

Announcements

PharmedOut’s annual conference: Missing The Target: When Practitioners Harm More Than Heal

No Free Lunch is merging with Healthy Skepticism

Conference program: Pharma Knows Best? Managing Medical Knowledge

Prescrire’s proposals for France’s national conference on medicines policy

Pharmed Out Conference ‘Pharma Knows Best? Managing Medical Knowledge’

More announcements

What's new on this site

Library Home

Library Search

...to influence multinational corporations effectively, the efforts of governments will have to be complemented by others, notably the many voluntary organisations that have shown they can effectively represent societyâ€™s public-health interestsâ€¦
A small group known as Healthy Skepticism; formerly the Medical Lobby for Appropriate Marketing) has consistently and insistently drawn the attention of producers to promotional malpractice, calling for (and often securing) correction. These organisations [Healthy Skepticism, MÃ©decins Sans FrontiÃ¨res and Health Action International] are small, but they are capable; they bear malice towards no one, and they are inscrutably honest. If industry is indeed persuaded to face up to its social responsibilities in the coming years it may well be because of these associations and others like them.
- Dukes MN. Accountability of the pharmaceutical industry. Lancet. 2002 Nov 23; 360(9346)1682-4.